You are here
Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation
Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.
On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.
Inflammation Immunology Pipeline & Trials
Immunology Pipeline as of October 29, 2019
- Discovery Projects
-
2Phase 1
-
15Phase 2
-
3Phase 3
-
3Registration
- Total23
|
Compound Name |
Indication |
Phase |
Submission Type |
Compound Type |
|---|---|---|---|---|
|
crisaborole (PF-06940799)
Therapeutic Area:
Inflammation & Immunology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
PDE4 Inhibitor |
Atopic Dermatitis (E.U.) | Registration | New Molecular Entity | Small Molecule |
|
PF-06410293, a potential biosimilar to Humira® (adalimumab)
Therapeutic Area:
Inflammation & Immunology Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma Mechanism of Action:
Tumor Necrosis Factor Inhibitor |
Rheumatoid Arthritis (Biosimilar) (U.S. / E.U.) | Registration | Biosimilar | Biosimilar |
|
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK Inhibitor |
Modified Release 11mg Tablet for Rheumatoid Arthritis (E.U.) | Registration | Product Enhancement | Small Molecule |
|
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK Inhibitor |
Atopic Dermatitis (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
|
PF-06651600
Therapeutic Area:
Inflammation & Immunology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK3/TEC |
Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
|
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK Inhibitor |
Ankylosing Spondylitis | Phase 3 | Product Enhancement | Small Molecule |
|
Dekavil
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM Mechanism of Action:
IL-10 |
Rheumatoid Arthritis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
|
Dekavil
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM Mechanism of Action:
IL-10 |
Inflammatory Bowel Disease (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
PF-06480605
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM Mechanism of Action:
TNFSF15 Blocker |
Ulcerative Colitis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
|
PF-06650833
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM Mechanism of Action:
IRAK4 |
Rheumatoid Arthritis | Phase 2 | New Molecular Entity | Small Molecule |
|
PF-06651600
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK3/TEC |
Rheumatoid Arthritis | Phase 2 | Product Enhancement | Small Molecule |
|
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK3/TEC; TYK2/JAK1 |
Ulcerative Colitis | Phase 2 | New Molecular Entity | Small Molecule |
|
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK3/TEC; TYK2/JAK1 |
Crohn's Disease | Phase 2 | Product Enhancement | Small Molecule |
|
PF-06651600 / PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
JAK3/TEC; TYK2/JAK1 |
Vitiligo | Phase 2 | Product Enhancement | Small Molecule |
|
PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM Mechanism of Action:
TYK2/JAK1 |
Alopecia Areata | Phase 2 | New Molecular Entity | Small Molecule |
|
PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM Mechanism of Action:
TYK2/JAK1 |
Psoriatic Arthritis | Phase 2 | New Molecular Entity | Small Molecule |
|
PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM Mechanism of Action:
TYK2/JAK1 |
Lupus | Phase 2 | Product Enhancement | Small Molecule |
|
PF-06700841
Therapeutic Area:
Inflammation & Immunology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM Mechanism of Action:
Topical TYK2/JAK1 |
Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
